0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ICOS

ICOS

ICOS Molecule Information

Name:Inducible T-cell costimulator
Target Synonym:Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein,Activation-inducible lymphocyte immunomediatory molecule
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 3 Clinical

ICOS Protein Product ListCompare or Buy

ICOS Part of Bioactivity data

ICS-M52H8-ELISA
Mouse ICOS (C137S, C138S), His TagMouse ICOS (C137S, C138S), His Tag (Cat. No. ICS-M52H8) ELISA bioactivity

Immobilized Human B7-H2, Fc Tag (Cat. No. B72-H5254) at 5 μg/mL (100 μL/well) can bind Mouse ICOS (C137S, C138S), His Tag (Cat. No. ICS-M52H8) with a linear range of 39-625 ng/mL (QC tested).

ICS-M5259-ELISA
Mouse ICOS (C137S, C138S), Fc TagMouse ICOS (C137S, C138S), Fc Tag (Cat. No. ICS-M5259) ELISA bioactivity

Immobilized Human B7-H2, His Tag (Cat. No. B72-H5221) at 1 μg/mL (100 μL/well) can bind Mouse ICOS (C137S, C138S), Fc Tag (Cat. No. ICS-M5259) with a linear range of 0.3-10 ng/mL (QC tested).

ICOS Molecule Synonym Name

ICOS,CD278,AILIM,Inducible T-cell costimulator

ICOS Molecule Background

Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

ICOS References

ICOS Related Molecule

ICOS Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
KY-1044 KY-1044 Phase 2 Clinical Kymab Liver Neoplasms; Head and Neck Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular Details
ALPN-101 ALPN-101 Phase 1 Clinical Alpine Immune Sciences Graft vs Host Disease; Autoimmune Diseases; Lymphoproliferative Disorders; Inflammation Details
Anti-ICOS (Bristol Myers Squibb) BMS-986226 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
Vopratelimab JTX-2011 Phase 2 Clinical Jounce Therapeutics Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
XmAb-23104 (Xencor) Phase 1 Clinical Xencor Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Sarcoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
GSK-3359609 GSK-3359609 Phase 3 Clinical Glaxosmithkline Plc Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma Details

This web search service is supported by Google Inc.

totop